Enlyton has secured worldwide exclusive licenses to a diverse intellectual property portfolio, with 5 issued U.S. and foreign patents, and pending U.S. and foreign patent applications. Our exclusive licenses include both composition of matter patents and production methods patents providing protection and the freedom to operate for our entire imaging platform.
Collectively, Enlyton’s intellectual property addresses novel molecular targeting agents for use in:
• cancer imaging
• detection and surgical removal of known and occult cancerous tissue in real-time
• surgical margin assessment
Legal Council — Pepper Hamilton, Pittsburgh PA